Moderna MRNA shares are trading lower after Japan on Thursday suspended 1.6 million doses of the company's COVID-19 vaccine following contamination reports.
Japan's health ministry said that 'foreign materials' were found in some doses of a batch of COVID-19 vaccines and suspended the batches out of an 'abundance of caution.'
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020.
At the time of publication, shares were trading 4.6% lower at $381.92.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
